Drugs / AMG 780
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01137552 | Jun 2010 → Dec 2013 | cancer | Amgen | Terminated | No outcome recorded Stop: Business |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMG 780 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01137552 ↗ |
| Action | Inhibit | “Angiopoietin-1 inhibitor” CHEMBL2109586 ↗1“Angiopoietin-2 inhibitor” CHEMBL2109586 ↗ |
| Route | Intravenous | “AMG 780 will be administered by IV infusion every 2 weeks” NCT01137552 ↗ |
| Target | ANGPT1 | “Angiopoietin-1 inhibitor” CHEMBL2109586 ↗ |
| Target | ANGPT2 | “Angiopoietin-2 inhibitor” CHEMBL2109586 ↗ |